| Overview |
| bsm-70256M |
| SARS-CoV-2 S-Protein ACE2 Binding Domain Antibody |
| WB, ICC |
| Specific for the ~25 kDa ACE2 binding domain construct of SARS-CoV-2 S protein. Full-length CoV-2 S protein is ~142 kDa. |
| SARS-CoV-2 |
| Specifications |
| Unconjugated |
| Mouse |
| Recombinant SARS-CoV-2 S-Protein construct containing the ACE2 binding domain expressed in and purified from E. coli. |
| Monoclonal |
| 5G8 |
| IgG1 |
| Lot Dependent |
| Purified by Protein G. |
| PBS + 50% glycerol and 5 mm NaN3 |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| P0DTC2 |
| The novel SARS-coronavirus 2 (SARS-CoV-2) which causes the disease COVID-19 has been shown to utilize the SARS-CoV receptor ACE2 for entry into human cells (Hoffman, M. et al., Cell 2020). The entry of a coronavirus into host cells is mediated by the viral surface-anchored transmembrane spike (S) glycoprotein which is composed of two functional subunits, S1 which binds the receptor and S2 which fuses the membrane (Walls, AC et.al., Cell 2020). S1 contains a receptor-binding domain (RBD) which specifically recognizes ACE2 as its receptor (Wan, Y. et al., 2020). |
| Application Dilution |
| WB |
1:300-5000 |
| ICC |
1:100-500 |
Powered by Bioz